1998;6:51S179S.9813653 [Google Scholar] [21].Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ
A randomized, double-blind, placebo-controlled, parallel-group study showed that among the patients with T2DM treated with EX monotherapy, EX could improve glycated hemoglobin, fasting blood glucose, and postprandial blood glucose control, reduce weight, improve cell function, and adjust blood pressure
Glutathione is a powerful antioxidant that plays a key role in neutralizing free radicals and supporting the body's natural detoxification processes
A series of large-scale randomized controlled trials (RCTs) demonstrated that SGLT2i use reduced the risk of kidney disease progression in patients with and without diabetes ( post hoc analysis of SUSTAIN6 and PIONEER6 demonstrated that semaglutide slowed the eGFR decline in T2D patients with a high risk of CVD ( With combination therapy of SGLT2i and GLP1Ra, the preceding drug did not affect the renal outcome in the main analysis of RECAP study ( post hoc analysis, the SGLT2i-preceding group had a slower rate of eGFR decline in comparison to the GLP1Ra-preceding group, and multiple regression analysis identified the preceding of SGLT2i as an independent and significant factor of change in eGFR decline
2 (Pt 4), pp
